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Hand-foot  syndrome  (HFS)  is  a  well-known  adverse  event  associated  with  capecitabine,  a  prodrug  of  5-Fluorouracil 
(5-FU).  HFS  manifests  as  acral  erythema,  with  swelling  and  dysesthesia  of  the  palms  and  plantar  aspects  of  the  feet, 
which  in  the  absence  of  dosage  reduction  or  drug  cessation,  progresses  to  moist  desquamation  and  ulceration, 
resulting  in  serious  infections  and  loss  of  function.  We  report  a  case  of  HFS,  with  scleroderma-like  changes,  apparently 
induced  by  capecitabine.  In  our  case,  capecitabine,  given  in  the  recommended  dosage  was  observed  to  lead  to 
hyperpigmentation  of  the  palms  and  soles,  followed  by  a  distinct  keratoderma-like  thickening  unfamiliar  to  usual  cases 
of  HFS.  This  case  may  provide  important  clues  for  revising  the  definition  of  HFS,  and  allow  the  formation  of  effective 
preventive  strategies  for  this  side  effect  of  chemotherapy. 
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INTRODUCTION 
Capecitabine  (Xeloda)  is  an  oral  fluoropyrimidine  carbamate, 
which  is  converted  to  its  only  active  metabolite,  FU,  by 
thymidine  phosphorylase.  Higher  levels  of  this  enzyme  are 
found  in  several  tumors,  as  well  as  the  liver,  compared  with 
normal  healthy  tissue
1-3).  The  localization  of  this  enzyme  to  liver 
and  tumor  tissues  allows  for  targeted  intratumoral  release  of  FU, 
with  subsequently  less  systemic  toxicity  than  with  i.v.  FU,  as 
documented  in  clinical  trials
3-5). 
The  most  common  dose-limiting  adverse  effects  associated 
with  capecitabine  monotherapy  are  hyperbilirubinemia,  diarrhea 
and  hand  foot  mouth  disease  (HFS).  Myelosuppression,  fatigue 
and  weakness,  abdominal  pain  and  nausea  have  also  been 
reported  as  potential  side  effects
6). 
HFS  is  a  cutaneous  adverse  effect,  also  referred  to  as 
palmar-plantar  erythrodysesthesia.  It  has  been  clinically 
described  as  a  condition  affecting  the  palms  of  the  hands  and 
the  soles  of  the  feet.  Patients  with  HFS  experience  various 
degrees  of  dysesthesia,  painful  erythema  and  edema,  which 
may  be  followed  by  dry  or  moist  desquamation  of  the  involved 
skin.  In  more  severe  cases,  the  symptoms  interfere  with  the 
normal  activities  of  daily  living.  A  grading  system  for  HFS  has 
been  developed,  incorporating  both  clinical  and  functional 
domains
7). 
Drugs  have  been  associated  with  HFS,  including  5-FU, 
capecitabine,  cytarabine,  doxorubicin,  epirubicin,  fluorodeoxyuri-
dine  (FUDR),  hydroxyurea,  mercaptopurine,  cyclophosphamide, 
docelaxel  and  vinorelbine
8). 
Herein  is  report  a  case  of  HFS,  with  scleroderma-like 
changes  induced  by  capecitabine. 
CASE REPORT 
A  70-year  old  male,  after  undergoing  a  palliative 
gastrojejunostomy  in  December  2003,  was  diagnosed  with  a 
stage  IV  signet  ring  cell  carcinoma  of  the  stomach.  He  received 
Figure  1.  Views  of  the  palms  and  soles. 
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Figure  2.  (A)  A  diffuse  increase  in  the  number  and  in 
thickness  of  collagen  bundles  throughout  the  reticular 
dermis  (H&E,  x100).  (B)  Note:  thickened  collagen  bundles 
(H&E,  x400).  (C)  Mild  perivascular  infiltration  of  chronic 
inflammatory  cells  is  observed  in  the  superficial  dermis.  In 
the  basal  layer  of  the  epidermis,  mild  spongiosis,  with 
exocytosis  of  a  few  small  lymphocytes,  is  apparent  (H&E, 
x200). 
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palliative  chemotherapy,  with  5-FU  and  taxotere  for  6  courses, 
5-FU,  irinotecan  and  leukovorin  for  3  courses,  and  5-FU  and 
heptaplatin  for  3  courses.  In  December  2004,  computed 
tomography  (CT)  scans  revealed  a  stable  disease  with 
peritoneal  seeding.  The  patient  then  received  oral  capecitabine 
(Xeloda)  chemotherapy,  at  a  daily  dosage  of  2500  mg/m
2,  in 
divided  doses.  Each  cycle  of  therapy  consisted  of  2  weeks  of 
capecitabine  administration,  followed  by  a  1-week  resting 
period.  After  the  fourth  course,  the  clinician  noted  desquamation 
and  brownish  to  black  hyperpigmentation  on  the  palms,  fingers 
and  soles.  The  patient  also  complained  of  mild  pain  in  his 
palms  and  soles,  but  denied  any  paresthesia.  Because  the 
patient's  only  concurrent  medications  were  azintamide,  almagate 
and  metoclopramide  HCl,  the  HFS  was  attributed  to 
capecitabine.  He  was  instructed  to  apply  lotion  to  his  hands  and 
feet  in  the  absence  of  dosage  reduction  or  cessation  of  the 
drug.  After  the  16th  course,  the  clinician  noted  a  scleroderma- 
like  change  with  hyperpigmentation  of  the  fingers  and  palms 
(Figure  1).  The  patient  experienced  mild  pain  and  discomfort 
when  using  his  hands,  which  interfered  with  hand  grasping.  A 
punch  biopsy  of  the  skin  from  the  finger  was  performed  (Figure 
2).  Histologically,  there  were  foci  of  mild  perivascular  infiltration 
of  chronic  inflammatory  cells,  with  some  scattered  pigment- 
laden  macrophages  in  the  superficial  dermis.  Dermal  sclerosis, 
with  thickening  of  collagen  bundles,  was  noted  throughout  the 
reticular  dermis.  In  the  basal  layer  of  the  epidermis,  mild 
spongiosis  with  exocytosis  of  a  few  small  lymphocytes  was 
noted.  The  search  for  antinuclear,  anticentromere,  anti-Scl  70 
antibodies  and  rheumatoid  factor  was  negative.  The  next  round 
of  chemotherapy  was  stopped  in  January  2006.  The  scleroderma- 
like  changes  gradually  improved  within  the  subsequent  3  to  4 
months  of  capecitabine  cessation. 
DISCUSSION 
5-FU  has  been  known  to  cause  HFS  since  the  association 
was  first  described  by  Lokich  and  Moore  in  1984
9).
  Compared 
with  bolus  infusion,  continuous  infusion  of  5-FU  is  associated 
with  a  higher  incidence  of  this  side  effect
10).  In  addition, 
continued  prolonged  exposure  to  5-FU,  provided  by  oral 
administration  of  capecitabine,  leads  to  rates  of  HFS  as  high  as 
68%
7). 
The  manifestations  of  HFS  are  classified  into  3  grades 
according  to  their  severity
11).  Grade  1  consists  of  erythema  of 
the  lateral  aspects  of  the  fingers  that  progress  to  the  thenar  and 
hypothenar  eminences,  with  swelling,  numbness,  dysesthesia/ 
paresthesia  and  tingling,  especially  over  the  pads  of  the  distal 
phalanges.  The  same  manifestations  occur  on  the  soles,  but 
less  frequently  on  the  dorsal  aspects  of  the  hands  and  feet. 
Grade  2  is  a  progression  of  grade-2  manifestations,  where  pain 
and  discomfort  affect  the  daily  activities  of  the  patient.  Grade  3 
is  the  superimposition  of  blistering,  moist  desquamation  and 
ulceration,  coupled  with  severe  pain. 
Of  the  adverse  reactions  of  capecitabine  HFS  is  listed  first  in 
the  drug's  product  information  provided  by  the  manufacturer
11), 
with  cessation  of  the  medication  recommended  for  grades  2 
and  3  HFS  until  the  event  is  resolves  or  decreases  in  intensity. 
Recognition  and  identification  of  the  signs  and  symptoms  of 
grade  1  HFS  in  patient  receiving  capecitabine  are  important  to 
avoid  progression  to  grade  2  or  to  the  more  debilitating  grade  3. 
Most  importantly;  however,  the  manifestations  of  HFS  in 
patients  are  different  from  those  described  in  the  literature.  First, 
our  developed  a  progressive  hyperpigmentation  of  his  palms, 
fingers  and  soles  rather  than  erythema.  Second,  there  was  a 
concomitant  gradual  thickening  of  the  skin  of  the  palms,  fingers 
and  soles,  which  lead  to  stiffness  of  the  hands  and  feet. 
In  another  case  report
12),  Parthas,  et  al  observed  that  the 
administration  of  capecitabine  lead  to  hyperpigmentation  of  the 
palms  and  soles,  followed  by  a  distinct  keratoderma-like 
thickening  in  3  black  patients.  They  suggested  that  the 
definitions  for  grades  1,  2  and  3  HFS  for  black  patients  should 
be  revised.  We  also  feel  that  the  definition  of  grade  1  HFS 
should  be  revised  to  include  hyperpigmentation  of  the  palms, 
fingers  and  soles,  either  with  or  without  erythema,  and  that 
progression  to  grade  2  HFS  should  consist  of  keratoderma-like 
thickening,  as  in  the  report  of  Parthas,  et  al. 
The  pathophysiology  of  HFS  is  largely  unknown,  with  only  a 
few  cases  having  been  investigated  via  biopsies.  Pathological 
changes  described  thus  far  include,  vacuolar  degeneration  of 
basal  keratinocytes,  dermal  perivascular  lymphocytic  infiltration, 
apoptotic  keratinocytes  and  dermal  edema
13,  14).
  In  this  case, 
dermal  sclerosis,  with  thickening  of  collagen  bundles,  was  noted 
throughout  the  reticular  dermis. 
In  a  case  report  of  HFS  in  black  patients
12),  the  result  of  a 
punch  biopsy  showed  vacuolar  degeneration  of  the  basal  layer 
of  the  epidermis,  with  cellular  enlargement,  spongiosis,  mild 
exocytosis  of  small  lymphocytes  and  marked  hyperkeratosis. 
The  dermis  showed  a  mild  superficial  perivascular  lymphocytic 
infiltrate. 
We  report  a  case  of  HFS,  with  scleroderma-like  change, 
which  was  apparently  induced  by  capecitabine.  More  research 
will  be  required  to  look  at  the  true  incidence  of  HFS  from  a 
variety  of  causes.  Continued  research  may  lead  to  the  discovery 
of  more  effective  strategies  for  the  prevention  and  treatment  of 
this  complication  of  chemotherapy,  and  allow  a  better  under-
standing  of  the  biology  and  pathophysiology  of  fluoropyrimidine. The  Korean  Journal  of  Internal  Medicine  :  Vol.  22,  No.  2,  June  2007 112
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